SEC Stock Data Quick Answer Zurn Elkay Water Solutions Corp reported Revenue (ASC 606) of $1.70 billion for fiscal year 2025. Zurn Elkay Water Solutions Corp Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $1.70B +8.3% 2024 $1.57B +2.4% 2023 $1.53B +19.4% 2022 $1.28B +40.7% 2021 $910.90M +22.1% 2020 $746.10M +5.1% 2020 … Read more
Quick Answer Zurn Elkay Water Solutions Corp reported Total Revenue of $1.70 billion for fiscal year 2025. Zurn Elkay Water Solutions Corp Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $1.70B +8.3% 2024 $1.57B +2.4% 2023 $1.53B +19.4% 2022 $1.28B +40.7% 2021 $910.90M +22.1% 2020 $746.10M +5.1% 2020 $710.10M -65.4% 2019 … Read more
Quick Answer Zurn Elkay Water Solutions Corp reported Total Revenue of $1.70 billion for fiscal year 2025. Zurn Elkay Water Solutions Corp — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $1.70B+8.3% $1.57B+2.4% $1.53B+19.4% $1.28B+40.7% $910.90M+28.3% $710.10M-65.4% Revenue (ASC 606) $1.70B+8.3% $1.57B+2.4% $1.53B+19.4% $1.28B+40.7% $910.90M+28.3% $710.10M-65.4% Net Income $198.00M+23.6% $160.20M+42.1% … Read more
Quick Answer ZyVersa Therapeutics, Inc. reported Shares Outstanding of 8.10 million shares for fiscal year 2025. ZyVersa Therapeutics, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 8.10M +222.8% 2024 2.51M +523.6% 2023 402,205 +56.1% 2022 257,604 — Quarterly Shares Outstanding Quarter Ending Shares Outstanding YoY QoQ September 30, 2025 8.10M … Read more
Quick Answer ZyVersa Therapeutics, Inc. reported Operating Income of -$25.49 million for fiscal year 2025. ZyVersa Therapeutics, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$25.49M -179.0% 2024 -$9.14M +91.5% 2023 -$107.75M -13039.7% 2022 -$820.1K +93.7% 2022 -$13.01M — Quarterly Operating Income Quarter Ending Operating Income YoY QoQ September 30, … Read more
Quick Answer ZyVersa Therapeutics, Inc. reported R&D Expense of $1.11 million for fiscal year 2025. ZyVersa Therapeutics, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $1.11M -37.4% 2024 $1.78M -44.5% 2023 $3.21M +702.1% 2022 $399.9K -92.6% 2022 $5.41M — Quarterly R&D Expense Quarter Ending R&D Expense YoY QoQ September 30, … Read more
Quick Answer ZyVersa Therapeutics, Inc. reported Stockholders Equity of -$12.39 million for fiscal year 2025. ZyVersa Therapeutics, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 -$12.39M -245.4% 2024 $8.52M -23.1% 2023 $11.07M -88.9% 2022 $99.66M -0.0% 2022 $99.68M +4513.7% 2021 -$2.26M — Quarterly Stockholders Equity Quarter Ending Stockholders Equity YoY … Read more
Quick Answer ZyVersa Therapeutics, Inc. reported Cash and Equivalents of $928.4 thousand for fiscal year 2021. ZyVersa Therapeutics, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2021 $928.4K — Quarterly Cash and Equivalents Quarter Ending Cash and Equivalents YoY QoQ September 30, 2022 $213.6K — -37.2% June 30, 2022 … Read more
Quick Answer ZyVersa Therapeutics, Inc. reported Total Assets of $347.9 thousand for fiscal year 2025. ZyVersa Therapeutics, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $347.9K -98.3% 2024 $20.60M -6.9% 2023 $22.11M -81.3% 2022 $118.51M +53.6% 2021 $77.14M — Quarterly Total Assets Quarter Ending Total Assets YoY QoQ September 30, … Read more
Quick Answer ZyVersa Therapeutics, Inc. reported Diluted EPS of $4.18 per share (loss) for fiscal year 2025. ZyVersa Therapeutics, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$4.18 +50.7% 2024 -$8.48 +99.2% 2023 -$1089.70 -375658.6% 2022 -$0.29 +70.7% 2022 -$0.99 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ … Read more